tbuckley/cabot-search huggingface dataset:
FRI0214 Incidence of pancreatic autoantibodies in primary sjÖgren syndrome
Authors: K Aksu, G Altan Oder, Y Kabasakal, G Keser, V Inal, A Isik, S Cetinkalp, E Doganavsargil
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Primary Sjögren (SjS) syndrome is one of the prototypes of autoimmune diseases. <h3>Objectives</h3> We aimed to work out the incidence of pancreatic autoantibodies in this disease. <h3>Methods</h3> Seventy-six patients (F/M: 71/5, mean age: 49 ± 13 years) diagnosed as primary SjS syndrome according to the San Diego criteria between February 1997 and December 2000, have been included in the study. Twenty two, age matched (52 ± 10 years) female patients with secondary SjS due to rheumatoid arthritis were defined as the control group. Healthy control group included 22 age matched (F/M: 21/1) patients. Immunosuppressive drug usage, liver or renal failure were within the exclusion criteria. Serum samples for anti-insulin (AIA), islet (ICA) and anti-insulin receptor (IRA) antibodies were obtained from all patients after an 18 h fasting. <h3>Results</h3> The incidence of anti-insulin antibody was found as 17%, while it was 7% and%17 for islet antibodies and anti-receptor antibodies, respectively (Table 1). These values were not statistically significant when compared with secondary SjS and healthy control groups (p &gt; 0.05). <h3>Conclusion</h3> Incidence of pancreatic auto-antibodies in primary SjS with observed hyperactivity of B cells, was not found statistically different when compared with patient and healthy control groups.
An Accelerated Wound‐Healing Surgical Suture Engineered with an Extracellular Matrix
Authors: Agustina Setiawati, Dongyoon Jang, Daeyon Cho, Shingyu Cho, Hayan Jeong, Sungmin Park, Jungsug Gwak, Soo Ryeon Ryu, Won Hee Jung, Bong‐Gun Ju, Kwang‐Hwan Jung, Oh‐Sun Kwon, Kwanwoo Shin
Journal: Advanced Healthcare Materials (2021)

Abstract A suture is a ubiquitous medical device to hold wounded tissues together and support the healing process after surgery. Surgical sutures, having incomplete biocompatibility, often cause unwanted infections or serious secondary trauma to soft or fragile tissue. In this research, UV/ozone (UVO) irradiation or polystyrene sulfonate acid (PSS) dip‐coating is used to achieve a fibronectin (FN)‐coated absorbable suture system, in which the negatively charged moieties produced on the suture cause fibronectin to change from a soluble plasma form into a fibrous form, mimicking the actions of cellular fibronectin upon binding. The fibrous fibronectin coated on the suture can be exploited as an engineered interface to improve cellular migration and adhesion in the region around the wounded tissue while preventing the binding of infectious bacteria, thereby facilitating wound healing. Furthermore, the FN‐coated suture is found to be associated with a lower friction between the suture and the wounded tissue, thus minimizing the occurrence of secondary wounds during surgery. It is believed that this surface modification can be universally applied to most kinds of sutures currently in use, implying that it may be a novel way to develop a highly effective and safer suture system for clinical applications.
Combination Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma—Reply
Authors: Michael J. Wagner, Lee D. Cranmer, Seth M. Pollack
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
An 11-week school-based ‘health education through football programme’ improves health knowledge related to hygiene, nutrition, physical activity and well-being—and it’s fun! A scaled-up, cluster-RCT with over 3000 Danish school children aged 10–12 years old
Authors: Malte Nejst Larsen, Anne-Marie Elbe, Mads Madsen, Esben Elholm Madsen, Christina Ørntoft, Knud Ryom, Jiri Dvorak, Peter Krustrup
Journal: British Journal of Sports Medicine (2021)

Objectives Our large-scale cluster randomised controlled trial aimed to investigate the effects on health knowledge and enjoyment of an 11 week ‘health education through football’ programme for children aged 10–12 years old. Methods 3127 Danish school children (49% girls) aged 10–12 years from a total of 154 schools located in 63% of the Danish municipalities (69 of 98) took part in the analysis. A 5:1 cluster randomisation was performed at school level for the intervention group (IG) or the control group (CG). The twice-weekly 45 min intervention was the ‘11 for Health in Denmark’ programme, which includes health education, football drills and small-sided games. The health education element focused on hygiene, nutrition, physical activity and well-being. Outcomes: The participants completed a 34-item multiple-choice computer-based health knowledge questionnaire preintervention and postintervention. IG also evaluated whether the programme was enjoyable. Results Between-group differences (p&lt;0.05) were observed in overall health knowledge in favour of IG (+7.2% points, 95% CI 6.1% to 8.4%, effect size, ES:0.59), with similar effects for girls (+7.4% points, 95% CI 5.9% to 9.0%, ES:0.57) and for boys (+7.0% points, 95% CI 5.3% to 8.7%, p&lt;0.05, ES:0.51). Marked between-group differences were observed in favour of IG, for health knowledge related to hygiene (IG vs CG:+13.9% points, 95% CI 11.1% to 16.7%, ES:0.53), nutrition (+10.3% points, 95% CI 8.5% to 12.1%, ES:0.53), physical activity (+5.9% points, 95% CI 4.1% to 7.7%, ES:0.36) and well-being (+4.4% points, 95% CI 2.7% to 6.1%, ES:0.28). Both girls and boys gave the programme moderate to high scores for enjoyment (3.6±1.0 and 3.7±1.1, respectively). Conclusion Health education through sport, using the ‘11 for Health’ model, was enjoyable for girls and boys aged 10–12 years old, and improved health knowledge related to hygiene, nutrition, physical activity and well-being.
Separate and Unequal: Race-Based Algorithms and Implications for Nephrology
Authors: Insa M. Schmidt, Sushrut S. Waikar
Journal: Journal of the American Society of Nephrology (2021)

In October 2018, the Journal of the American Medical Association published a series of articles on race and racism in medicine and the health sciences.[1][1][⇓][2]–[3][3] Drawing on historical examples of the cruel and unethical clinical experimentation on enslaved women[1][1] and emphasizing
The impact of autoantibodies against citrullinated, carbamylated, and acetylated peptides on radiographic progression in patients with new-onset rheumatoid arthritis: an observational cohort study
Authors: Jagtar S Nijjar, Fraser R Morton, Holger Bang, Christopher D Buckley, Désirée van der Heijde, Ashley Gilmour, Caron Paterson, Iain B McInnes, Duncan Porter, Karim Raza, Cosimo De Bari, Margaret Duncan, Susan Fraser, Mohini Gray, Lisa Hutton, John Harvie, Vinod Kumar, Mike McMahon, Robin Munro, John Larkin, Neil McKay, John McLaren, Stuart Ralston, David M Reid, Ruth Richmond, Gillian Roberts, Sarah Saunders, Hilary Wilson
Journal: The Lancet Rheumatology (2021)
Telomerase reverse transcriptase (hTERT) overexpression protects cancer cells from ROS mediated cell death
Authors: Inthrani Indran, Manoor Hande, Shazib Pervaiz
Journal: Cancer Research (2008)

1835  Human telomerase reverse transcriptase (hTERT) is the catalytic subunit of the telomerase holoenzyme, required for telomerase maintenance and often re-activated in human cancers. By dint of these activities, hTERT has been widely used for cellular immortalization. However recent advances in the telomerase field suggest new functions for hTERT in conferring increased resistance against apoptosis inducing agents and DNA damaging drugs. In an effort to unravel the biological activity of this remarkable protein, we are investigating the cross talk between hTERT and cellular redox status during the process of carcinogenesis. To that end, our work over the years has highlighted the death inhibitory and/or tumor promoting activity of a slight pro-oxidant state, invariably associated with the neoplastic phenotype. For example, we linked the death inhibitory activity of Bcl-2 to its ability to create a slight pro-oxidant state in tumor cells. In addition, recent evidence has linked an increase in Bcl-2 expression to increased telomerase activity. Intrigued by these findings, we are interested in asking if tumor cell redox status could affect hTERT expression and activity and vice versa. To do so, we stably overexpressed hTERT in HeLa cells, and demonstrate that hTERT overexpression affects intracellular ROS status. We hypothesize that alteration(s) in intracellular redox status upon overexpression of hTERT may modify tumor cell response to apoptotic death triggers. In this regard, we provide evidence that hTERT may play a crucial role in regulating mitochondria mediated cell death pathway. These data provide a novel biological activity of hTERT, which could have implications for designing effective therapeutic strategies against cancer cells. The molecular mechanisms of altered ROS balance by hTERT and interaction of hTERT with pro-apoptotic proteins and their effect on cell fate is currently the focus of our studies.
EPEN-31. SINGLE-CELL RNAseq OF CHILDHOOD EPENDYMOMA REVEALS DISTINCT NEOPLASTIC CELL SUBPOPULATIONS THAT IMPACT ETIOLOGY, MOLECULAR CLASSIFICATION AND OUTCOME
Authors: Andrew Donson, Austin Gillen, Riemondy Kent, Ahmed Gilani, Sujatha Venkataraman, Bridget Sanford, Andrea Griesinger, Vladimir Amani, Todd Hankinson, Michael Handler, Jay Hesselberth, Rajeev Vibhakar, Nicholas Foreman
Journal: Neuro-Oncology (2020)

Abstract Ependymoma (EPN) is a brain tumor commonly presenting in childhood that remains fatal in the majority of children. Intra-tumoral cellular heterogeneity in bulk-tumor samples significantly confounds our understanding of EPN biology, impeding development of effective therapy. We therefore used single-cell RNA sequencing to catalog cellular heterogeneity of 26 childhood EPN, predominantly from ST-RELA, PFA1 and PFA2 subgroups. ST-RELA and PFA subgroups clustered separately, with ST-RELA clustering largely according to individual sample-of-origin. PFA1 and PFA2 subgroup EPNs cells were intermixed and revealed 4 major subpopulations – 2 with characteristics of ependymal differentiation (transporter and ciliated phenotype subpopulations), an undifferentiated subpopulation and a mesenchymal phenotype. Pseudotime analysis showed the undifferentiated progenitor subpopulation either differentiating into ependymal differentiation subpopulations or transitioning into the mesenchymal subpopulation. Histological analysis revealed that undifferentiated and mesenchymal subpopulations cells colocalized to perinecrotic/perivascular zones, the putative ependymoma stem cell niche. Deconvolution of PFA bulk transcriptome data showed that undifferentiated and mesenchymal subpopulations were associated with a poor prognosis; whereas the ciliated ependymal cell-differentiated subpopulation was associated with a good prognosis. In conflict with current distinct classification paradigms, the ratio of mesenchymal and ciliated subpopulations determined bulk-tumor subgroups assignment to PFA1 and PFA2 respectively. This atlas of EPN cellular heterogeneity provides an important advance in our understanding of EPN biology, identifying high-risk associated subpopulations for therapeutic targeting.
SAT0040 Rheumatic diseases in patients with vitiligo: a study on 28 cases
Authors: I Olivieri, G Ciancio, A Padula, L La Civita, A Piccirillo, F Ricciuti, F Cantini, L Niccoli, C Salvarani
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Recently, we have demonstrated in a case-control study that vitiligo and spondyloarthropathy (SpA) do not coexist by chance in the same patient.<sup>1</sup> Of the 234 patients with SpA seen in the study period 8 (3.4%) were found to be suffering from type A vitiligo. On the contrary, among the 468 control patients only 5 (1.06%) had type A vitiligo. The difference was statistically significant (p &lt; 0.05). <h3>Objectives</h3> To establish the reasons for the rheumatological consultation in consecutive patients with vitiligo seen for the first time in our department. <h3>Methods</h3> All patients that showed visible type A vitiligo in peri-orificial sites (around mouth, nose, eyes) and/or over the extensor surfaces of hands and wrists, seen for the first time in our department from January 1999 to 31 December 2000, were evaluated clinically. X-ray and laboratory examinations were performed when necessary. <h3>Results</h3> Twenty-eight patients with visible vitiligo were seen. Of these, 4 had inflammatory rheumatic diseases associated with vitiligo (2 elderly onset undifferentiated SpA, 2 psoriatic arthritis, 1 rheumatoid arthritis together with lupus profundus). Five patients had inflammatory rheumatic diseases with dubious relationships with vitiligo (3 polymyalgia-like syndrome, 1 seronegative chronic polyarthritis, 1 severe peripheral enthesitis). The remaining 17 patients had vitiligo unrelated rheumatic diseases including osteoarthritis, mechanical low back pain, herniated disc, spondylolisthesis, condrocalcinosis, rotator cuff tendinitis, olecranic bursitis and trigger finger. Seven out of the 28 patients had diseases of the thyroid gland and 1 alopecia areata. <h3>Conclusion</h3> The results of the present study confirm the association between vitiligo and SpA. Some patients with vitiligo have undifferentiated inflammatory rheumatic diseases, which need to be followed up. <h3>Reference</h3> Padula A, <i>et al</i>. Association between vitiligo and spondyloarthropathy. J Rheumatol. 2001;<b>28,</b> in press
Reflections of a Naïve Trainee to Barnes Jewish Hospital/Washington University in 1970—My First 25 Years
Authors: Aubrey R. Morrison
Journal: Journal of the American Society of Nephrology (2021)

"Aubrey, I didn't know you were that smart," said my colleague, a White faculty member who had known me for years, after I presented a research seminar in 1980. I brushed this off at the time, but in retrospect, it was one of many microaggressions I experienced in my early days at Washington
AB0225 Prevalence of rheumatic diseases in general medicine practice in portugal
Authors: PJ Clemente-Coelho, ML Marques-Matos
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Rheumatic Diseases are of the most important causes of morbidity in our society, with high social and economic repercussion. <h3>Objectives</h3> To study the prevalence of rheumatic diseases in general practise and their implications related to chronic use of medication and work absenteeism. <h3>Methods</h3> Prospective study with observance of the consecutive patients in a general practitioner appointment during a period of six months. <h3>Results</h3> 1219 appointments corresponding to 591 patients were analysed. Rheumatic complaints were the most prevalent motive of appointment (21%) followed by cardiovascular diseases (14,7%) and psychiatric diseases (12,2%). The most frequent rheumatic diseases were soft-tissue rheumatism, including low-back pain and other vertebral pain (48,5%) and osteoarthritis (18,1%). Rheumatic diseases were the third cause of chronic use of medication, after psychiatric diseases and gastric-intestinal diseases. Rheumatic diseases were the first cause of work absenteeism with a total of 42,5% od days lost in work in the active patients group. Among the rheumatic diseases, low-back pain and osteoarthritis were the main causes of work absenteeism, but rheumatoid arthritis was the disease of higher level of individual morbidity. <h3>Conclusion</h3> Rheumatic diseases are a very prevalent problem in the primary health care level in Portugal and have an important repercussion in the social and economic field.
Understanding the impact of COVID incancer patients through the COVID-19 and Cancer (CCC-19) and other COVID consortiums
Authors: B. I. Rini
Journal: Clinical Cancer Research (2020)

SARS-CoV-2 and the resulting disease, COVID-19, has led to a global pandemic with broad impact on the deliveryof medical care  Cancer patients may be especially vulnerable to both infection and adverse outcomes from COVIDdue to a number of factors including advanced age, immunosuppression from disease and/or anticancer therapy, and heightened interaction with the medical system  Several cohort studies have been launched to more fullyunderstand risk factors for death and other adverse outcomes in patients with active or remote cancer  CCC-19 is acohort study involving more than 100 institutions that enter data into a REDCaP database regarding patientdemographics, cancer type and treatment details, and outcome of COVID infection  All patients have documentedSARS-CoV-2 PCR positive and/or clinical symptoms consistent with COVID, in addition to an ongoing or past historyof invasive malignancy  The initial analysis of this cohort study (n=928;Kuderer et al , Lancet 2020) demonstrated a13% mortality rate and revealed several factors associated with an increased mortality including advanced age, male gender, greater number of comorbidities, worse ECOG performance status, and progressive cancer  Recentcancer surgery and receipt of cytotoxic or other systemic anticancer therapy was not associated with worseoutcome, although small patient numbers in some subsets precluded definitive conclusions  At present, there areapproximately 3,000 patients entered into this database and updated analyses will be presented  In addition to thiseffort, a number of other societies have created similar databases including ASH, ASCO, and ESMO  Thesecomplementary efforts will allow a global assessment of the impact of COVID on cancer patients including mortalityand adverse outcomes in addition to cancer-specific outcomes  Last, the NCI COVID-19 in Cancer Patients Study(NCCAPS) is a prospective study in patients with active cancer and recent SARS-CoV-2 infection  This 2,000-patient study is open to accrual and will prospectively define both the impact of COVID on cancer and also cancerstatus and treatment on COVID outcome  In addition, biospecimen collection in this study will examine geneticpredisposition, cytokine and coagulopathic parameters, and serologic outcomes  Collectively, these retrospectiveand prospective efforts will enable a more granular understanding of COVID in cancer patients to enable bothappropriate cancer care delivery and improvement in outcomes in cancer patients with COVID infection
E-Cigarettes, Vaping, and Youth
Authors: Lawrence O. Gostin, Aliza Y. Glasner
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer
Authors: Ali Ghoochani, En-Chi Hsu, Merve Aslan, Meghan A. Rice, Holly M. Nguyen, James D. Brooks, Eva Corey, Ramasamy Paulmurugan, Tanya Stoyanova
Journal: Cancer Research (2021)

Abstract Ferroptosis is a type of programmed cell death induced by the accumulation of lipid peroxidation and lipid reactive oxygen species in cells. It has been recently demonstrated that cancer cells are vulnerable to ferroptosis inducers (FIN). However, the therapeutic potential of FINs in prostate cancer in preclinical settings has not been explored. In this study, we demonstrate that mediators of ferroptosis, solute carrier family 7 member 11, SLC3A2, and glutathione peroxidase, are expressed in treatment-resistant prostate cancer. We further demonstrate that treatment-resistant prostate cancer cells are sensitive to two FINs, erastin and RSL3. Treatment with erastin and RSL3 led to a significant decrease in prostate cancer cell growth and migration in vitro and significantly delayed the tumor growth of treatment-resistant prostate cancer in vivo, with no measurable side effects. Combination of erastin or RSL3 with standard-of-care second-generation antiandrogens for advanced prostate cancer halted prostate cancer cell growth and migration in vitro and tumor growth in vivo. These results demonstrate the potential of erastin or RSL3 independently and in combination with standard-of-care second-generation antiandrogens as novel therapeutic strategies for advanced prostate cancer. Significance: These findings reveal that induction of ferroptosis is a new therapeutic strategy for advanced prostate cancer as a monotherapy and in combination with second-generation antiandrogens.